Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 22
- Registration Number
- NCT02440568
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02441803
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 3100
- Registration Number
- NCT02416388
- Locations
- 🇫🇷
CH Amiens Hôpital Sud, Amiens, France
🇫🇷CHU Angers, Angers, France
🇫🇷CH Victor Dupouy, Argenteuil, France
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02400281
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 158
- Registration Number
- NCT02339740
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Naval Medical Center -San Diego, San Diego, California, United States
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 97
- Registration Number
- NCT02310321
- Locations
- 🇯🇵
Site JP81037, Anjo, Aichi, Japan
🇯🇵Site JP00003, Nagoya, Aichi, Japan
🇯🇵Site JP81003, Nagoya, Aichi, Japan
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
- Conditions
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 91
- Registration Number
- NCT02306291
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02283177
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- GSO Global Clinical Research BV
- Target Recruit Count
- 42
- Registration Number
- NCT02249091
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02236013
- Locations
- 🇺🇸
Site US10003, Los Angeles, California, United States
🇺🇸Site US10013, New Haven, Connecticut, United States
🇺🇸Site US10004, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.